Session » Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 909

A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 863

Arterial Lesions in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 860

Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 879

Associated Inflammatory Diseases in Takayasu’s Arteritis: The Many Faces of a Disease

9:00AM-11:00AM: Abstract Number: 881

Cardiopulmonary Involvement in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 891

Clinal Characterisitics and Diagnosis of Patients with Negative Temporal Artery Biopsy and without a Final Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 904

Clinical Features and Mortality of 411 Chinese Takayasu’s Arteritis Patients

9:00AM-11:00AM: Abstract Number: 901

Clinical Features of Takayasu’s Arteritis from an Inception Cohort: Early Disease Is Characterized By ‘systemic Inflammation’

9:00AM-11:00AM: Abstract Number: 870

Contemporary Prevalence Estimates for Giant Cell Arteritis and Polymyalgia Rheumatica, 2015

9:00AM-11:00AM: Abstract Number: 897

Discordance Rates of Bilateral Temporal Artery Biopsies: A Retrospective Analysis

9:00AM-11:00AM: Abstract Number: 899

Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases

9:00AM-11:00AM: Abstract Number: 861

Efficacy of Methotrexate in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 874

Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19) in Giant-Cell Arteritis Lesions. Potential Role of p40 in Promoting Th1 -Mediated Pathways

9:00AM-11:00AM: Abstract Number: 887

Fatigue and Physical Functioning in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 892

FDG-PET CT Evaluation By Visual Grading Is Not Sufficiently Discriminative to Assess Disease Activity in Takayasu’s Arteritis Patients with ‘Persistent’ Disease

9:00AM-11:00AM: Abstract Number: 883

Folate Receptor Beta and Endothelin Receptor Beta Macrophage Subtypes Are Differentially Expressed in the Vascular Compartments of the Intima and Media/Adventitia in Giant Cell Arteritis: A Pilot Study

9:00AM-11:00AM: Abstract Number: 885

Giant Cell Arteritis and Malignancy – More Than Just a Coincidence?

9:00AM-11:00AM: Abstract Number: 878

Giant-Cell Arteritis Related Stroke: A Retrospective Multicentre Case-Control Study

9:00AM-11:00AM: Abstract Number: 890

Health-Related Domains of Importance to Patients with Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 884

Health-Related Quality of Life in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 902

High Disease Activity Scores and Leptin Levels in Takayasu Patients with Overweight and Obesity

9:00AM-11:00AM: Abstract Number: 895

Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 868

Infections and the Risk of Incident Giant Cell Arteritis: A Population-Based, Case-Control Study

9:00AM-11:00AM: Abstract Number: 871

Interleukin 33 Critically Regulates Angiogenesis and Inflammation in Large Vessels Vasculitis

9:00AM-11:00AM: Abstract Number: 873

Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 858

Is There a Place for Repetitive 18f-Fluorodeoxyglucose Positron Emission Tomography in Giant-Cell Arteritis with Large-Vessel Involvement?

9:00AM-11:00AM: Abstract Number: 894

Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?

9:00AM-11:00AM: Abstract Number: 876

Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 859

Long-Term Outcomes of Renal Artery Involvement in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 869

Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 872

New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study

9:00AM-11:00AM: Abstract Number: 875

Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment

9:00AM-11:00AM: Abstract Number: 866

Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?

9:00AM-11:00AM: Abstract Number: 880

Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?

9:00AM-11:00AM: Abstract Number: 905

Platelet Activation, As Measured By Plasma Soluble Glycoprotein VI, Is Not Associated with Disease Activity or Ischaemic Events in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 882

Polymyalgia Rheumatica Activity Score without C-Reactive Protein

9:00AM-11:00AM: Abstract Number: 865

Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 893

Preliminary Results of a Multi Modal Imaging Study Suggests a Better Accuracy for the Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 888

Prevalence of Takayasu Arteritis in Young Women Presenting with Acute Ischemic Heart Disease

9:00AM-11:00AM: Abstract Number: 856

Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy

9:00AM-11:00AM: Abstract Number: 896

Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 877

Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 907

Rituximab in Patients with Takayasu Arteritis: A Single Center Experience on Five Patients

9:00AM-11:00AM: Abstract Number: 864

Takayasu Arteritis Developed over the Age of 40 Has Lower Levels of Interferon Gamma and Interleukin 17 at Disease Onset and Fewer Subsequent Relapses

9:00AM-11:00AM: Abstract Number: 903

Temporal Arteritis: Is There Any Correlation Between Ultrasonographic Arterial Wall Involvement and the Inflammatory Cellular Infiltrate at Histological Examination?

9:00AM-11:00AM: Abstract Number: 867

Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)

9:00AM-11:00AM: Abstract Number: 900

The Phenotype of Macrophages in the Inflamed Vascular Wall of Giant Cell Arteritis Resembles the Phenotype of Non-Classical Monocytes

9:00AM-11:00AM: Abstract Number: 889

The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 898

Treatment and Outcome of Patients with a Diagnosis of Healed Arteritis on Temporal Artery Biopsy

9:00AM-11:00AM: Abstract Number: 906

Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice

9:00AM-11:00AM: Abstract Number: 857

Ultrasound Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 862

Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 908

Utilization of Multiple Acute Phase Proteins and Biomarkers for Giant Cell Arteritis – Insight into Diagnosis and Clinical Complications

9:00AM-11:00AM: Abstract Number: 886

Vascular Inflammation Assessed By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) Is Modified By Treatment in Patients with Large Vessel Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].